PE-22-28: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •3 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 40 community reports
- •2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Species Translation | All published PE-22-28 research is in rodent models. The key study used intraperitoneal injection at 0.1 mg/kg in mice. PE-22-28 demonstrated antidepressant-like effects in forced swimming and novelty suppressed feeding tests, and promoted hippocampal neurogenesis within 4 days. | Community uses fixed doses of 100-400 mcg intranasally or subcutaneously. Human equivalent dose calculation from the mouse IP data is not straightforward given the route differences. | high PE-22-28 has never been tested in humans. All community protocols are extrapolated entirely from mouse data. The antidepressant-like effects observed in rodent behavioral tests do not necessarily translate to human antidepressant effects. |
| Administration Route | Mouse studies used intraperitoneal (IP) injection. No intranasal or subcutaneous studies have been published. | Community primarily uses intranasal spray for direct CNS delivery or subcutaneous injection. Neither route has been studied for PE-22-28 in any species. | high The community routes (intranasal, SubQ) have no published data for PE-22-28. Bioavailability via these routes is completely unknown. |
| Safety Profile | No formal toxicology or safety studies have been published for PE-22-28. The published data is limited to efficacy endpoints in mouse behavioral models. | Community reports generally describe PE-22-28 as well-tolerated, with lethargy at higher doses being the most commonly reported side effect. However, no systematic safety assessment exists. | high The absence of any safety or toxicology data is a significant concern. Community safety observations are limited to short-term subjective reports from a small number of users. |
Compare these community approaches with published research findings.
Community Protocols
Standard Intranasal Protocol
Popular- Route
- Intranasal
- Dose
- 200-400 mcg
- Frequency
- Once daily, morning
- Duration
- 4-8 weeks
Most commonly reported protocol; morning dosing preferred for mood and cognitive effects throughout the day
Low-Dose Subcutaneous Protocol
Common- Route
- Subcutaneous
- Dose
- 100-200 mcg
- Frequency
- Once daily
- Duration
- 4-8 weeks
SubQ injection as alternative to intranasal; some users report stronger effects but higher risk of lethargy at higher doses
Titration Protocol
Niche- Route
- Subcutaneous
- Dose
- 100 mcg starting, titrate to 150-200 mcg
- Frequency
- Once daily
- Duration
- 8-16 weeks with gradual titration
Conservative approach starting low and increasing based on response; recommended by some community guides
Stacking Patterns
PE-22-28 + Selank Mood Stack
NicheCombining TREK-1 channel blockade (PE-22-28) with GABAergic anxiolytic effects (Selank) for antidepressant and anxiolytic effects through complementary mechanisms
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 40+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Peptides|PE-22-28 experience reports and dosing discussions(accessed 2026-02-16)
- Reddit r/Nootropics|PE-22-28 spadin analog nootropic discussions(accessed 2026-02-16)
- PeptideDosages.com|PE-22-28 10mg Vial Dosage Protocol(accessed 2026-02-16)
- Jay Campbell|PE-22-28 The Antidepressant Peptide - Benefits, Dosage and Side Effects(accessed 2026-02-16)
- Peptide Affect|PE-22-28 peptide guide and protocol information(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for PE-22-28. The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
PE-22-28 is a synthetic spadin analog that has gained attention in the nootropics and peptide communities for its TREK-1 potassium channel blocking activity and preclinical antidepressant effects. Community interest is driven by the novel mechanism of action and the rapid hippocampal neurogenesis observed in mouse studies. However, PE-22-28 has never been tested in humans, and all community protocols are extrapolated from mouse research.
Understanding Protocol Divergence#
No Human Data#
The most critical consideration for PE-22-28 is that all evidence comes from mouse models. There are no human pharmacokinetic, safety, or efficacy studies. The antidepressant-like effects in rodent behavioral tests (forced swimming test, novelty suppressed feeding) are standard preclinical assays that do not always predict human antidepressant efficacy.
Route and Dose Extrapolation#
Mouse studies used intraperitoneal injection at 0.1 mg/kg. Community users employ intranasal or subcutaneous routes at fixed doses of 100-400 mcg. Neither route has been studied for PE-22-28, and bioavailability via intranasal or subcutaneous delivery is unknown.
Commonly Reported Outcomes#
Community members report the following effects from PE-22-28 use:
- Mood elevation: The most commonly reported benefit, described as improved motivation and emotional outlook
- Cognitive effects: Some users report enhanced focus and mental clarity, particularly at lower doses (under 400 mcg)
- Rapid onset: Users report noticeable effects within the first few days, consistent with the rapid neurogenesis observed in mouse models
- Lethargy: The most commonly reported side effect, particularly at doses above 500-600 mcg
- Dose sensitivity: Users emphasize the importance of finding the right dose, as too high can cause excessive sedation
Important Caveats#
- No human clinical trials have been conducted
- No formal safety or toxicology data exists
- Self-treatment of depression with unproven compounds is risky
- Mouse behavioral tests do not reliably predict human antidepressant effects
- Bioavailability via community-used routes is unknown
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About PE-22-28
What is the most common PE-22-28 community protocol?
The most widely reported PE-22-28 protocol is 200-400 mcg administered intranasally once daily in the morning. Some users prefer subcutaneous injection at 100-200 mcg daily. Community members recommend staying under 600 mcg to avoid lethargy, with doses around 400 mcg being considered optimal for cognitive and mood effects based on anecdotal reports. All protocols are entirely community-derived as PE-22-28 has never been tested in humans.
Does PE-22-28 cause lethargy?
Lethargy or excessive sedation is the most commonly reported side effect at higher doses (above 500-600 mcg). Some community members report that staying at or below 400 mcg provides cognitive enhancement and mood improvement without significant sedation. This dose-dependent effect may relate to the mechanism of TREK-1 channel blockade, which affects neuronal excitability. Starting at a low dose and titrating upward is the standard community recommendation.
How does PE-22-28 compare to conventional antidepressants?
Community members report that PE-22-28 provides mood elevation and motivation enhancement with a faster onset (days rather than weeks) compared to SSRIs. However, these comparisons are entirely anecdotal. PE-22-28 has a novel mechanism (TREK-1 channel blockade) distinct from SSRIs (serotonin reuptake inhibition). No human clinical trials have been conducted, so direct comparison with approved antidepressants is not possible. Self-treatment of depression with unproven peptides carries serious risks.
Can PE-22-28 promote neurogenesis?
In mouse studies, PE-22-28 promoted hippocampal neurogenesis after only 4 days of treatment, which is faster than the neurogenic effects typically seen with SSRIs. This is one of the main claims driving community interest. However, mouse hippocampal neurogenesis does not directly predict human brain effects, and no human neurogenesis studies exist for PE-22-28.
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.